

## Reflex Genomic Testing for Unresectable Non-Small Cell Lung Cancer (NSCLC) or Carcinoma, Suspected Lung Primary

The lung cancer transdisciplinary team at UVMMC, based on review of advances in medical knowledge and practice, have unanimously decided to implement reflex genomic testing by the GenePanel Solid Tumor assay and PD-L1 immunohistochemical staining (PD-L1 IHC) for unresectable NSCLC or unresectable “carcinoma that may likely be from a non-small cell lung primary”. Currently, most samples of unresectable NSCLC or unresectable “carcinoma that may likely be from a non-small cell lung primary” at our institution, are submitted for targeted genomic analysis by the GenePanel Solid Tumor and many for PD-L1 IHC.

To decrease the turnaround time in getting these results to the providers to be able to use the information to plan possible treatment, reflex testing will be initiated by pathology.

- Reflex testing criteria: Any sample deemed in the morphologic review to be “NSCLC” or “carcinoma, suspected lung cancer primary” (not applicable to small cell lung cancer) AND is deemed unresectable/advanced stage, will have genomic analysis and PD-L1 initiated in the reflex pathway.
  - Test algorithm: N/A

**Effective Date:** 2/5/2018

Initial Test	Reflex Criteria	Reflex Test(s)	Additional CPT Billed
Microscopic analysis of anatomic pathology specimen	Microscopic Diagnoses of “Non-small cell lung cancer” OR “carcinoma, suspected lung cancer primary” AND designated unresectable	GenePanel Solid Tumor	81445
		PD-L1 Immunochemistry	88360

### PATHOLOGY & LABORATORY MEDICINE

111 Colchester Avenue | Mail Stop: 233MP1 | Burlington, Vermont 05401

### PHONE LABORATORY CUSTOMER SERVICE

(802) 847-5121 | (800) 991-2799

### TEST CATALOG

[UVMLabs.TestCatalog.org/](http://UVMLabs.TestCatalog.org/)